S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)

Beyond Air (XAIR) Competitors

$1.25
+0.06 (+4.62%)
(As of 02:30 PM ET)

XAIR vs. APYX, DXR, AMIX, HSAQ, SRTS, CTSO, NSPR, CTCX, LUCD, and ICU

Should you be buying Beyond Air stock or one of its competitors? The main competitors of Beyond Air include Apyx Medical (APYX), Daxor (DXR), Autonomix Medical (AMIX), Health Sciences Acquisitions Co. 2 (HSAQ), Sensus Healthcare (SRTS), Cytosorbents (CTSO), InspireMD (NSPR), Carmell (CTCX), Lucid Diagnostics (LUCD), and SeaStar Medical (ICU). These companies are all part of the "surgical & medical instruments" industry.

Beyond Air vs.

Apyx Medical (NASDAQ:APYX) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 13.1% of Apyx Medical shares are owned by company insiders. Comparatively, 19.0% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Apyx Medical currently has a consensus target price of $6.17, suggesting a potential upside of 376.19%. Beyond Air has a consensus target price of $11.25, suggesting a potential upside of 822.13%. Given Apyx Medical's higher possible upside, analysts plainly believe Beyond Air is more favorable than Apyx Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apyx Medical
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beyond Air
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Beyond Air has a net margin of 0.00% compared to Beyond Air's net margin of -35.75%. Beyond Air's return on equity of -54.90% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Apyx Medical-35.75% -54.90% -28.41%
Beyond Air N/A -199.90%-106.00%

In the previous week, Apyx Medical and Apyx Medical both had 1 articles in the media. Apyx Medical's average media sentiment score of 1.29 beat Beyond Air's score of 0.00 indicating that Beyond Air is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apyx Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beyond Air
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Apyx Medical has higher revenue and earnings than Beyond Air. Apyx Medical is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apyx Medical$52.35M0.87-$18.71M-$0.54-2.44
Beyond AirN/AN/A-$55.82M-$2.13-0.58

Apyx Medical received 34 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.25% of users gave Beyond Air an outperform vote while only 61.60% of users gave Apyx Medical an outperform vote.

CompanyUnderperformOutperform
Apyx MedicalOutperform Votes
77
61.60%
Underperform Votes
48
38.40%
Beyond AirOutperform Votes
43
68.25%
Underperform Votes
20
31.75%

Apyx Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500.

Summary

Apyx Medical beats Beyond Air on 8 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XAIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XAIR vs. The Competition

MetricBeyond AirSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$44.87M$3.69B$4.80B$7.36B
Dividend YieldN/A2.21%2.92%4.01%
P/E Ratio-0.5812.76201.7915.49
Price / SalesN/A57.492,475.0989.11
Price / CashN/A43.3946.8834.82
Price / Book0.894.174.554.17
Net Income-$55.82M$3.75M$103.81M$214.16M
7 Day Performance-13.54%-3.02%-4.16%-3.32%
1 Month Performance-18.63%-7.42%-5.76%-3.78%
1 Year Performance-79.18%12.63%6.75%3.58%

Beyond Air Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APYX
Apyx Medical
3.868 of 5 stars
$1.39
+0.7%
$6.17
+343.6%
-54.0%$48.15M$52.35M-2.57252
DXR
Daxor
0 of 5 stars
$9.55
+0.5%
N/AN/A$45.27MN/A0.00N/AGap Up
AMIX
Autonomix Medical
0 of 5 stars
$2.78
-5.4%
N/AN/A$52.25MN/A0.001
HSAQ
Health Sciences Acquisitions Co. 2
0 of 5 stars
$4.66
-3.7%
N/A-76.2%$52.25MN/A0.004
SRTS
Sensus Healthcare
2.9664 of 5 stars
$3.20
flat
$7.50
+134.4%
-37.7%$52.45M$24.41M106.7035News Coverage
Positive News
CTSO
Cytosorbents
1.1363 of 5 stars
$0.80
-8.1%
$2.50
+213.4%
-74.9%$43.31M$36.35M-1.25186Positive News
Gap Up
NSPR
InspireMD
1.9949 of 5 stars
$2.25
-0.9%
$4.85
+115.6%
+105.8%$52.79M$6.20M-2.0865Analyst Report
CTCX
Carmell
0 of 5 stars
$2.20
-8.7%
N/AN/A$42.35MN/A0.0014Gap Down
High Trading Volume
LUCD
Lucid Diagnostics
1.8941 of 5 stars
$0.82
flat
$2.75
+237.4%
-45.6%$39.32M$2.43M-0.6470Negative News
ICU
SeaStar Medical
0.9957 of 5 stars
$0.71
+7.6%
$5.00
+603.9%
-75.2%$39.15MN/A0.009Gap Down

Related Companies and Tools

This page (NASDAQ:XAIR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners